Ubiquitin- and ATP-Independent Proteolytic Turnover of p21 by the REGγ-Proteasome Pathway

Molecular Cell

Volumn 26, Issue 6, 2007, Pages 831-842

  Li, Xiaotao ^a   Amazit, Larbi ^a   Long, Weiwen ^a   Lonard, David M ^a   Monaco, John J ^b   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

CELLCYCLE; PROTEINS

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEASOME; PROTEIN; PROTEIN P21; PROTEIN REG GAMMA; STEROID RECEPTOR COACTIVATOR 3; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PURIFICATION; RNA INTERFERENCE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; AUTOANTIGENS; CELL CYCLE; CELL-FREE SYSTEM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HELA CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; MICE; MICE, KNOCKOUT; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, SMALL INTERFERING; THYROID NEOPLASMS; TRANS-ACTIVATORS; UBIQUITIN;

EID: 34250339984     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2007.05.028     Document Type: Article

References (38)

1. Asher G., Tsvetkov P., Kahana C., and Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 19 (2005) 316-321
2. Barton L.F., Runnels H.A., Schell T.D., Cho Y., Gibbons R., Tevethia S.S., Deepe Jr. G.S., and Monaco J.J. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J. Immunol. 172 (2004) 3948-3954
3. Bendjennat M., Boulaire J., Jascur T., Brickner H., Barbier V., Sarasin A., Fotedar A., and Fotedar R. UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 114 (2003) 599-610
4. Bloom J., Amador V., Bartolini F., DeMartino G., and Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115 (2003) 71-82
5. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
6. Cascio P., Call M., Petre B.M., Walz T., and Goldberg A.L. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J. 21 (2002) 2636-2645
7. Cayrol C., Knibiehler M., and Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16 (1998) 311-320
8. Chen X., Chi Y., Bloecher A., Aebersold R., Clurman B.E., and Roberts J.M. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Mol. Cell 16 (2004) 839-847
9. Clurman B.E., Sheaff R.J., Thress K., Groudine M., and Roberts J.M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10 (1996) 1979-1990
10. Coste A., Antal M.C., Chan S., Kastner P., Mark M., O'Malley B.W., and Auwerx J. Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J. 25 (2006) 2453-2464
11. Coulombe P., Rodier G., Bonneil E., Thibault P., and Meloche S. N-terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome. Mol. Cell. Biol. 24 (2004) 6140-6150
12. Dubiel W., Pratt G., Ferrell K., and Rechsteiner M. Purification of an 11 S regulator of the multicatalytic protease. J. Biol. Chem. 267 (1992) 22369-22377
13. Dupont J., Karas M., and LeRoith D. The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells. J. Biol. Chem. 278 (2003) 37256-37264
14. Hagemann C., Patel R., and Blank J.L. MEKK3 interacts with the PA28 gamma regulatory subunit of the proteasome. Biochem. J. 373 (2003) 71-79
15. Li J., and Rechsteiner M. Molecular dissection of the 11S REG (PA28) proteasome activators. Biochimie 83 (2001) 373-383
16. Li X., Lonard D.M., Jung S.Y., Malovannaya A., Feng Q., Qin J., Tsai S.Y., Tsai M.J., and O'Malley B.W. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124 (2006) 381-392
17. Liu C.W., Corboy M.J., DeMartino G.N., and Thomas P.J. Endoproteolytic activity of the proteasome. Science 299 (2003) 408-411
18. Lonard D.M., Tsai S.Y., and O'Malley B.W. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol. Cell. Biol. 24 (2004) 14-24
19. Ma C.P., Slaughter C.A., and DeMartino G.N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. 267 (1992) 10515-10523
20. Marcelli M., Stenoien D.L., Szafran A.T., Simeoni S., Agoulnik I.U., Weigel N.L., Moran T., Mikic I., Price J.H., and Mancini M.A. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J. Cell. Biochem. 98 (2006) 770-788
21. Moriishi K., Okabayashi T., Nakai K., Moriya K., Koike K., Murata S., Chiba T., Tanaka K., Suzuki R., Suzuki T., et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J. Virol. 77 (2003) 10237-10249
22. Murata S., Kawahara H., Tohma S., Yamamoto K., Kasahara M., Nabeshima Y., Tanaka K., and Chiba T. Growth retardation in mice lacking the proteasome activator PA28gamma. J. Biol. Chem. 274 (1999) 38211-38215
23. Niculescu III A.B., Chen X., Smeets M., Hengst L., Prives C., and Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18 (1998) 629-643
24. Nikaido T., Shimada K., Shibata M., Hata M., Sakamoto M., Takasaki Y., Sato C., Takahashi T., and Nishida Y. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 79 (1990) 209-214
25. Okamura T., Taniguchi S., Ohkura T., Yoshida A., Shimizu H., Sakai M., Maeta H., Fukui H., Ueta Y., Hisatome I., and Shigemasa C. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J. Clin. Endocrinol. Metab. 88 (2003) 1374-1383
26. Ouyang B., Knauf J.A., Smith E.P., Zhang L., Ramsey T., Yusuff N., Batt D., and Fagin J.A. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin. Cancer Res. 12 (2006) 1785-1793
27. Roninson I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179 (2002) 1-14
28. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., and Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 5 (2000) 403-410
29. Touitou R., Richardson J., Bose S., Nakanishi M., Rivett J., and Allday M.J. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J. 20 (2001) 2367-2375
30. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., and Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 9 (1999) 661-664
31. Varshavsky A. Regulated protein degradation. Trends Biochem. Sci. 30 (2005) 283-286
32. Varshavsky A., Turner G., Du F., and Xie Y. Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway. Biol. Chem. 381 (2000) 779-789
33. Weinberg W.C., and Denning M.F. P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral Biol. Med. 13 (2002) 453-464
34. Yan F., Gao X., Lonard D.M., and Nawaz Z. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol. Endocrinol. 17 (2003) 1315-1331
35. Ying H., Furuya F., Zhao L., Araki O., West B.L., Hanover J.A., Willingham M.C., and Cheng S.Y. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J. Clin. Invest. 116 (2006) 2972-2984
36. Zhang Z., Clawson A., Realini C., Jensen C.C., Knowlton J.R., Hill C.P., and Rechsteiner M. Identification of an activation region in the proteasome activator REGalpha. Proc. Natl. Acad. Sci. USA 95 (1998) 2807-2811
37. Zhou P. REGgamma: a shortcut to destruction. Cell 124 (2006) 256-257
38. Zhu Q., Wani G., Yao J., Patnaik S., Wang Q.E., El-Mahdy M.A., Praetorius-Ibba M., and Wani A.A. The ubiquitin-proteasome system regulates p53-mediated transcription at p21(waf1) promoter. Oncogene (2007) 10.1038/sj.onc.1210191 Published online January 15, 2007